methyl 7-(3-pyridinyl)-6-oxoheptanoate | 134162-93-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 7-(3-pyridinyl)-6-oxoheptanoate
• 英文别名: methyl 7-(pyridin-3-yl)-6-oxoheptanoate；methyl 7-(3-pyridyl)-6-oxoheptanoate；Methyl 6-oxo-7-pyridin-3-ylheptanoate
• CAS: 134162-93-9
• 化学式: C₁₃H₁₇NO₃
• 分子量: 235.283
• InChiKey: GCTXFMYPHDOSDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 7-(3-pyridinyl)-6-oxoheptanoate 在 palladium on activated charcoal 、 镍 氨 、 氢气 、 sodium hydride 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 5.0~25.0 ℃ 、303.98 kPa 条件下， 反应 15.0h， 生成 methyl 8-(p-chlorophenylsulfonamido)-6-(pyridin-3-ylmethyl)-octanoate
  参考文献：
  名称：

  Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids

  摘要：

  A series of 8-[(arylsulfonyl)amino]octanoic acids substituted with a pyridinylalkyl group along the chain were synthesized and tested in vitro for their ability to both antagonize the binding of thromboxane A2 to its receptors and to inhibit the thromboxane synthase enzyme. This series of compounds were found to inhibit the U 46619-induced aggregation of human platelets and the U 46619-induced contraction of dog saphenous vein. The compounds also inhibited TxA2 biosynthesis in a human microsomal platelet preparation. The relative position of the pyridinylalkyl and arylsulfonamido groups had significant effects on the thromboxane receptor antagonist (TxRA) activity and thromboxane synthase inhibitor (TxSI) activity. Compounds with the pyridine ring at the 7- or 8-position of the octanoic acid side chain were weakly active as TxSI but behaved as potent TxRA at the platelet receptor for TxA2. However, these compounds were agonists at the vascular receptor. Substitution of the pyridinylalkyl group at the 2- or 3-position resulted in compounds with potent TxSI activity and weak TxRA activity. The activity profile of the compounds with the pyridinylalkyl substitution at the 4-, 5-, or 6-position was very desirable. Compound 22 with a pyridinylpropyl substituent at the 4-position was found to display extremely potent TxRA and TxSI properties.

  DOI：

  10.1021/jm00101a014
• 作为产物：
  描述：

  7-(3-pyridyl)hept-6-enoic acid 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 水 、 sodium hydride 、 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 17.0h， 生成 methyl 7-(3-pyridinyl)-6-oxoheptanoate
  参考文献：
  名称：

  Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids

  摘要：

  A series of 8-[(arylsulfonyl)amino]octanoic acids substituted with a pyridinylalkyl group along the chain were synthesized and tested in vitro for their ability to both antagonize the binding of thromboxane A2 to its receptors and to inhibit the thromboxane synthase enzyme. This series of compounds were found to inhibit the U 46619-induced aggregation of human platelets and the U 46619-induced contraction of dog saphenous vein. The compounds also inhibited TxA2 biosynthesis in a human microsomal platelet preparation. The relative position of the pyridinylalkyl and arylsulfonamido groups had significant effects on the thromboxane receptor antagonist (TxRA) activity and thromboxane synthase inhibitor (TxSI) activity. Compounds with the pyridine ring at the 7- or 8-position of the octanoic acid side chain were weakly active as TxSI but behaved as potent TxRA at the platelet receptor for TxA2. However, these compounds were agonists at the vascular receptor. Substitution of the pyridinylalkyl group at the 2- or 3-position resulted in compounds with potent TxSI activity and weak TxRA activity. The activity profile of the compounds with the pyridinylalkyl substitution at the 4-, 5-, or 6-position was very desirable. Compound 22 with a pyridinylpropyl substituent at the 4-position was found to display extremely potent TxRA and TxSI properties.

  DOI：

  10.1021/jm00101a014

文献信息

• Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof
  申请人：CIBA-GEIGY AG

  公开号：EP0405391A1

  公开（公告）日：1991-01-02

  The present invention is concerned with compounds of formula I wherein A, B, M, R, Ar and Het are as defined in the specification, pharmaceutically acceptable ester and amide derivatives thereof; N-oxides thereof, tetrazole derivatives thereof, and salts thereof. These compounds have valuable pharmacological activities, especially as inhibitors of thromboxane synthetase and as receptor antagonists of thromboxane A₂ and prostaglandin H₂. They are prepared in a manner known per se.

  本发明涉及式 I 化合物（其中 A、B、M、R、Ar 和 Het 如说明书中所定义）、其药学上可接受的酯和酰胺衍生物、其 N-氧化物、其四唑衍生物及其盐类。 这些化合物具有重要的药理活性，特别是作为血栓素合成酶的抑制剂和血栓素 A₂及前列腺素 H₂的受体拮抗剂。 它们的制备方法本身是已知的。
• US5025025A
  申请人：——

  公开号：US5025025A

  公开（公告）日：1991-06-18
• US5153214A
  申请人：——

  公开号：US5153214A

  公开（公告）日：1992-10-06
• Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids
  作者：Alan J. Main、Shripad S. Bhagwat、Clay Boswell、Robert Goldstein、Candido Gude、David Cohen、Patricia Furness、Warren Lee、Marissa Louzan

  DOI：10.1021/jm00101a014

  日期：1992.11

  A series of 8-[(arylsulfonyl)amino]octanoic acids substituted with a pyridinylalkyl group along the chain were synthesized and tested in vitro for their ability to both antagonize the binding of thromboxane A2 to its receptors and to inhibit the thromboxane synthase enzyme. This series of compounds were found to inhibit the U 46619-induced aggregation of human platelets and the U 46619-induced contraction of dog saphenous vein. The compounds also inhibited TxA2 biosynthesis in a human microsomal platelet preparation. The relative position of the pyridinylalkyl and arylsulfonamido groups had significant effects on the thromboxane receptor antagonist (TxRA) activity and thromboxane synthase inhibitor (TxSI) activity. Compounds with the pyridine ring at the 7- or 8-position of the octanoic acid side chain were weakly active as TxSI but behaved as potent TxRA at the platelet receptor for TxA2. However, these compounds were agonists at the vascular receptor. Substitution of the pyridinylalkyl group at the 2- or 3-position resulted in compounds with potent TxSI activity and weak TxRA activity. The activity profile of the compounds with the pyridinylalkyl substitution at the 4-, 5-, or 6-position was very desirable. Compound 22 with a pyridinylpropyl substituent at the 4-position was found to display extremely potent TxRA and TxSI properties.